对174例多形性胶质母细胞瘤患者FLAIR MRI界定的肿瘤迁移路径行 upfront boost 伽玛刀「前缘」放射外科治疗:一种新疗法的15年评估
该研究回顾了174例新诊断多形性胶质母细胞瘤(GBM)患者,在标准放化疗前或期间对FLAIR MRI界定的肿瘤细胞迁移前缘(LE)行单次立体定向放射外科推量治疗(LERS)。中位总生存期为23个月,2年、3年、5年、7年和10年实际总生存率分别为39%、26%、16%、10%和4%。作者认为LERS是安全有效的辅助治疗,但研究为单中心经验且LE靶区由单一机构确定。
要点
- LERS靶区为对比增强肿瘤主体外、FLAIR MRI界定的区域,中位靶体积48.5 cm³,中位剂量8 Gy。
- LERS后中位总生存期23个月,2年、3年、5年、7年、10年实际总生存率分别为39%、26%、16%、10%、4%。
- 9%患者出现LERS相关影像学改变,19%因水肿、22%因肿瘤囊肿或新肿瘤团块切除、2%因脑积水分流而住院。
核心结论
- 作者认为LERS是对新诊断GBM患者安全有效的upfront辅助治疗。
研究设计与样本
- 回顾性分析2000年12月至2016年5月间174例新诊断GBM患者,在标准放疗和卡莫司汀或替莫唑胺化疗前或期间对肿瘤细胞迁移前缘行单次立体定向放射外科推量治疗。
- 患者中位年龄59岁(范围22-87岁),LERS距原诊断中位18天,LE靶区中位体积48.5 cm³(范围2.5-220.0 cm³),中位剂量8 Gy(范围6-14 Gy)于50%等剂量线。
主要发现
- 自诊断起中位总生存期为23个月(均值43个月)。
- LERS后2年、3年、5年、7年和10年实际总生存率分别为39%、26%、16%、10%和4%。
- 9%患者出现LERS相关影像学证实的治疗改变。
- 全程中19%患者因水肿管理住院,22%因肿瘤囊肿或新肿瘤团块切除住院,2%因脑积水分流住院。
- 存活患者中90%卡氏功能状态评分保持稳定,10%因症状性治疗相关影像改变下降1-3级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 单中心经验。
- LE肿瘤靶区由单一机构确定。
- 将描述前缘计算算法以实现LE靶区定义的统一方法以供普遍使用。
- 需多中心试验进一步阐明其在GBM治疗中的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Glioblastoma multiforme (GBM) is composed of cells that migrate through the brain along predictable white matter pathways. Targeting white matter pathways adjacent to, and leading away from, the original contrast-enhancing tumor site (termed leading-edge radiosurgery [LERS]) with single-fraction stereotactic radiosurgery as a boost to standard therapy could limit the spread of glioma cells and improve clinical outcomes. METHODS Between December 2000 and May 2016, after an initial diagnosis of GBM and prior to or during standard radiation therapy and carmustine or temozolomide chemotherapy, 174 patients treated with radiosurgery to the leading edge (LE) of tumor cell migration were reviewed. The LE was defined as a region outside the contrast-enhancing tumor nidus, defined by FLAIR MRI. The median age of patients was 59 years (range 22-87 years). Patients underwent LERS a median of 18 days from original diagnosis. The median target volume of 48.5 cm3 (range 2.5-220.0 cm3) of LE tissue was targeted using a median dose of 8 Gy (range 6-14 Gy) at the 50% isodose line. RESULTS The median overall survival was 23 months (mean 43 months) from diagnosis. The 2-, 3-, 5-, 7-, and 10-year actual overall survival rates after LERS were 39%, 26%, 16%, 10%, and 4%, respectively. Nine percent of patients developed treatment-related imaging-documented changes due to LERS. Nineteen percent of patients were hospitalized for management of edema, 22% for resection of a tumor cyst or new tumor bulk, and 2% for shunting to treat hydrocephalus throughout the course of their disease. Of the patients still alive, Karnofsky Performance Scale scores remained stable in 90% of patients and decreased by 1-3 grades in 10% due to symptomatic treatment-related imaging changes. CONCLUSIONS LERS is a safe and effective upfront adjunctive therapy for patients with newly diagnosed GBM. Limitations of this study include a single-center experience and single-institution determination of the LE tumor target. Use of a leading-edge calculation algorithm will be described to achieve a consistent approach to defining the LE target for general use. A multicenter trial will further elucidate its value in the treatment of GBM.
引用
- Duma CM, Kim BS, Chen PV, et al. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy. J Neurosurg. 2016. PMID: 27903197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。